$0.52 EPS Expected for Omnicell, Inc. (OMCL) This Quarter

Analysts expect that Omnicell, Inc. (NASDAQ:OMCL) will report earnings of $0.52 per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Omnicell’s earnings, with the lowest EPS estimate coming in at $0.52 and the highest estimate coming in at $0.53. Omnicell posted earnings per share of $0.37 in the same quarter last year, which suggests a positive year over year growth rate of 40.5%. The firm is scheduled to report its next earnings results on Wednesday, February 21st.

On average, analysts expect that Omnicell will report full year earnings of $1.31 per share for the current year, with EPS estimates ranging from $1.30 to $1.32. For the next fiscal year, analysts expect that the firm will post earnings of $1.96 per share, with EPS estimates ranging from $1.88 to $2.05. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Omnicell.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same period last year, the company earned $0.40 EPS. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year.

Several brokerages have recently weighed in on OMCL. Zacks Investment Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $60.00 price objective on shares of Omnicell in a report on Tuesday, December 5th. BidaskClub lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Friday, December 22nd. Oppenheimer reiterated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Thursday, October 19th. Finally, Craig Hallum reiterated a “buy” rating and set a $62.00 price objective (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $55.14.

In related news, VP Peter J. Kuipers sold 4,724 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.74, for a total value of $225,523.76. Following the transaction, the vice president now owns 40,544 shares in the company, valued at $1,935,570.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the transaction, the chief financial officer now owns 40,544 shares in the company, valued at approximately $2,095,719.36. The disclosure for this sale can be found here. Insiders sold 27,558 shares of company stock worth $1,330,230 in the last 90 days. 3.77% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. California Public Employees Retirement System raised its stake in shares of Omnicell by 4.2% during the second quarter. California Public Employees Retirement System now owns 81,200 shares of the company’s stock valued at $3,500,000 after purchasing an additional 3,300 shares during the period. Northern Trust Corp raised its stake in shares of Omnicell by 6.0% during the second quarter. Northern Trust Corp now owns 515,757 shares of the company’s stock valued at $22,230,000 after purchasing an additional 29,217 shares during the period. Kornitzer Capital Management Inc. KS raised its stake in shares of Omnicell by 20.8% during the third quarter. Kornitzer Capital Management Inc. KS now owns 155,240 shares of the company’s stock valued at $7,925,000 after purchasing an additional 26,700 shares during the period. Nationwide Fund Advisors raised its stake in shares of Omnicell by 6.0% during the second quarter. Nationwide Fund Advisors now owns 269,177 shares of the company’s stock valued at $11,602,000 after purchasing an additional 15,222 shares during the period. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Omnicell by 20.3% during the second quarter. Parametric Portfolio Associates LLC now owns 174,763 shares of the company’s stock valued at $7,532,000 after purchasing an additional 29,484 shares during the period. Institutional investors own 99.69% of the company’s stock.

Shares of Omnicell (NASDAQ OMCL) opened at $51.50 on Tuesday. Omnicell has a 12 month low of $32.70 and a 12 month high of $55.40. The stock has a market cap of $1,950.00, a PE ratio of -468.18, a price-to-earnings-growth ratio of 4.10 and a beta of 0.71. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/23/0-52-eps-expected-for-omnicell-inc-omcl-this-quarter.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply